interleukin-2

Synthekine hopes new IL-2 will be the high-alpha in a beta class

IL-2 medicines have shown the ability to kill tumors. Synthekine hopes to do this without the associated toxicities with a new IL-2 alpha/beta molecule.

Annalee Armstrong Apr 10, 2024 9:50am

Gilead pays $43.5M for Xilio's early-phase IL-12 prospect

Mar 28, 2024 8:08am

paint mural street artist spray paint woman painting

Mural wants to paint new picture in IL-2 after Alkermes spinout

Nov 15, 2023 8:56am

airplane divert change block no reject direction oath

Coya deems dementia drug R&D plan 'premature,' switches focus

Jun 12, 2023 9:00am

Neoleukin lays off 70% of staff, hunts for strategic alternative

Mar 9, 2023 5:45am

AstraZeneca deals another blow to IL-12 by dumping gene therapy

Feb 9, 2023 8:15am